Latest RIDGEFIELD Stories
- In the Phase III LUX-Lung 8 trial, afatinib significantly improved overall survival compared to erlotinib, reducing the risk of death by 19% in patients with advanced squamous cell carcinoma of the
STIOLTO RESPIMAT is the only COPD treatment that includes two proven agents: tiotropium, the active ingredient in SPIRIVA®, and olodaterol RIDGEFIELD, Conn., May 26, 2015 /PRNewswire/ -- Boehringer
Long-term OFEV treatment in the INPULSIS® extension study reinforces the safety and tolerability profile for up to 33 months in patients with IPF RIDGEFIELD, Conn., May 18, 2015 /PRNewswire/
- LUX-Lung 8 Phase III study evaluating the efficacy and safety of afatinib vs.
General Devices, a medical technology company specializing in innovative telemedicine and communications solutions, for hospitals, EMS & public safety, is now GD. Ridgefield,
The Largest Display of Sandwich Wraps will feature 750 Distinct Wraps made by Dozens of Local Volunteers RIDGEFIELD, N.J., April 19, 2015 /PRNewswire/ -- At 10:00am EST today,
RIDGEFIELD, Conn., April 6, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S.
-- Data show initial therapy in newly diagnosed NVAF patients diverged from guideline recommendations RIDGEFIELD, Conn., March 16, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals,
-- First BLA submission for an investigational reversal agent for a novel oral anticoagulant RIDGEFIELD, Conn., March 2, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Less than 1 in 3 patients and caregivers are prepared for how IPF will affect their daily life RIDGEFIELD, Conn., Feb.
- The parings of haberdine; also, any kind of fragments.